nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alastair Devlin discusses the concept of virtual pharma companies
|
Lawrence, Rebecca N |
|
2001 |
6 |
10 |
p. 508-509 2 p. |
artikel |
2 |
Are drug targets missed due to lack of physical activity? – Replys
|
Anderson, Brenda |
|
2001 |
6 |
10 |
p. 515- 1 p. |
artikel |
3 |
A sticky end for pathogens?
|
Owens, Joanna |
|
2001 |
6 |
10 |
p. 500-502 3 p. |
artikel |
4 |
Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery
|
Payne, David J |
|
2001 |
6 |
10 |
p. 537-544 8 p. |
artikel |
5 |
Combinatorial chemistry
|
Edwards, Paul |
|
2001 |
6 |
10 |
p. 547-549 3 p. |
artikel |
6 |
From DNA Damage and Stress Signalling to Cell Death
|
Nuttall, Mark E |
|
2001 |
6 |
10 |
p. 516- 1 p. |
artikel |
7 |
LPS inhibitors: key to overcoming multidrug-resistant bacteria?
|
Sansom, Clare |
|
2001 |
6 |
10 |
p. 499-500 2 p. |
artikel |
8 |
Molecular biology databases: today and tomorrow
|
Ellis, Lynda B.M |
|
2001 |
6 |
10 |
p. 509-513 5 p. |
artikel |
9 |
Monitor: molecules and profiles
|
Langston, Steven |
|
2001 |
6 |
10 |
p. 545-547 3 p. |
artikel |
10 |
Monoclonal antibody strategies to block angiogenesis
|
Hicklin, Daniel J |
|
2001 |
6 |
10 |
p. 517-528 12 p. |
artikel |
11 |
More collaboration needed between drug development and imaging communities
|
Mankoff, David A. |
|
2001 |
6 |
10 |
p. 514-515 2 p. |
artikel |
12 |
New opportunities for enhanced ovarian cancer prevention
|
Habeck, Martina |
|
2001 |
6 |
10 |
p. 502-503 2 p. |
artikel |
13 |
New quinolones and the impact on resistance
|
Dougherty, Thomas J |
|
2001 |
6 |
10 |
p. 529-536 8 p. |
artikel |
14 |
News in brief
|
Ramster, Ben |
|
2001 |
6 |
10 |
p. 504-506 3 p. |
artikel |
15 |
People
|
Lawrence, R |
|
2001 |
6 |
10 |
p. 507- 1 p. |
artikel |
16 |
Pharmacogenomics: challenges and opportunities
|
Peet, Norton P. |
|
2001 |
6 |
10 |
p. 495-498 4 p. |
artikel |